Health Care & Life Sciences » Biotechnology | ZIOPHARM Oncology Inc.

ZIOPHARM Oncology Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
800.00
1,373.00
4,332.00
6,861.00
6,389.00
146
Cost of Goods Sold (COGS) incl. D&A
-
462.00
-
-
-
-
Gross Income
-
911.00
-
-
-
-
SG&A Expense
55,304.00
44,410.00
114,075.00
171,878.00
59,513.00
53,479
EBIT
55,242.00
43,499.00
110,100.00
165,307.00
53,493.00
53,906
Unusual Expense
515.00
11,723.00
10,000.00
124.00
1,295.00
158
Non Operating Income/Expense
1,350.00
5.00
12.00
134.00
465.00
631
Pretax Income
57,107.00
31,781.00
120,088.00
165,297.00
54,323.00
53,117
Consolidated Net Income
57,107.00
31,781.00
120,088.00
165,297.00
54,323.00
53,117
Net Income
57,107.00
31,781.00
120,088.00
165,297.00
54,323.00
53,117
Net Income After Extraordinaries
57,107.00
31,781.00
120,088.00
165,297.00
54,323.00
260,478
Net Income Available to Common
57,107.00
31,781.00
120,088.00
172,420.00
73,261.00
70,115
EPS (Basic)
0.66
0.31
0.96
1.32
0.53
0.96
Basic Shares Outstanding
85,943.20
101,130.70
125,416.10
130,391.50
136,938.30
143,508.70
EPS (Diluted)
0.66
0.31
0.96
1.32
0.53
0.96
Diluted Shares Outstanding
85,943.20
101,130.70
125,416.10
130,391.50
136,938.30
143,508.70
EBITDA
54,504.00
43,037.00
109,743.00
165,017.00
53,124.00
53,333
Preferred Dividends
-
-
-
7,123.00
18,938.00
16,998

About ZIOPHARM Oncology

View Profile
Address
Parris Building
Boston Massachusetts 02129
United States
Employees -
Website http://www.ziopharm.com
Updated 07/08/2019
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of a diverse portfolio of cancer therapies. It focuses on developing products in immuno-oncology that employ novel gene expression, control, and cell technologies for the treatment of cancer. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.